Healthcare companies by risk reading
Healthcare companies by risk reading: 1,214 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 1 September 2026.
Composite readings for 8,308 companies, recomputed 1 September 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Lilly(Eli) & Company LLY | 17 | Contained | Healthcare | United States | 4 / 6 | $1.1T |
| Johnson & Johnson JNJ | 37 | Normal | Healthcare | United States | 4 / 6 | $640.2B |
| Abbvie Inc ABBV | 46 | Elevated | Healthcare | United States | 4 / 6 | $453.1B |
| Roche Holding AG RO | 32 | Normal | Healthcare | Switzerland | 5 / 6 | $370.1B |
| Merck & Co Inc MRK | 26 | Normal | Healthcare | United States | 5 / 6 | $364.8B |
| Novartis AG NVS | 25 | Normal | Healthcare | Switzerland | 5 / 6 | $278.4B |
| Astrazeneca plc AZN | 30 | Normal | Healthcare | United Kingdom | 5 / 6 | $251.4B |
| AMGEN Inc AMGN | 33 | Normal | Healthcare | United States | 4 / 6 | $232.4B |
| Thermo Fisher Scientific Inc TMO | 45 | Elevated | Healthcare | United States | 5 / 6 | $228.2B |
| Novo Nordisk A/S NOVO-B | 23 | Normal | Healthcare | Denmark | 3 / 6 | $206.4B |
| Abbott Laboratories ABT | 43 | Elevated | Healthcare | United States | 5 / 6 | $191.0B |
| Gilead Sciences Inc GILD | 31 | Normal | Healthcare | United States | 4 / 6 | $181.6B |
| Pfizer Inc PFE | 44 | Elevated | Healthcare | United States | 4 / 6 | $162.2B |
| Novo Nordisk NVO | 31 | Normal | Healthcare | Denmark | 5 / 6 | $151.7B |
| Danaher Corp DHR | 47 | Elevated | Healthcare | United States | 5 / 6 | $150.1B |
| Vertex Pharmaceuticals Inc VRTX | 20 | Normal | Healthcare | United States | 4 / 6 | $138.0B |
| Bristol-Myers Squibb Company BMY | 32 | Normal | Healthcare | United States | 4 / 6 | $136.5B |
| Intuitive Surgical Inc ISRG | 30 | Normal | Healthcare | United States | 4 / 6 | $133.4B |
| Stryker Corp SYK | 38 | Normal | Healthcare | United States | 5 / 6 | $124.2B |
| Medtronic Plc MDT | 42 | Elevated | Healthcare | Ireland | 4 / 6 | $116.0B |
| Sanofi SNY | 39 | Normal | Healthcare | France | 5 / 6 | $108.2B |
| Mckesson Corporation MCK | 43 | Elevated | Healthcare | United States | 5 / 6 | $102.7B |
| GSK Plc GSK | 32 | Normal | Healthcare | United Kingdom | 5 / 6 | $101.6B |
| GSK plc GS71 | 35 | Normal | Healthcare | United Kingdom | 4 / 6 | $100.5B |
| HCA Healthcare Inc HCA | 44 | Elevated | Healthcare | United States | 4 / 6 | $90.3B |
| EssilorLuxottica Société anonyme ESL | 52 | Elevated | Healthcare | France | 5 / 6 | $87.2B |
| ESSILORLUXOTTICA 1/2/O.N. ESLC | 51 | Elevated | Healthcare | France | 5 / 6 | $83.1B |
| Regeneron Pharmaceuticals Inc REGN | 35 | Normal | Healthcare | United States | 5 / 6 | $82.6B |
| Chugai Pharmaceutical Co., Ltd. 4519 | 35 | Normal | Healthcare | Japan | 4 / 6 | $72.5B |
| Boston Scientific Corp BSX | 34 | Normal | Healthcare | United States | 4 / 6 | $69.9B |
| Chugai Pharmaceutical Co., Ltd. CUP0 | 38 | Normal | Healthcare | Japan | 4 / 6 | $68.3B |
| Argen X SE ARGX | 12 | Contained | Healthcare | Netherlands | 5 / 6 | $64.2B |
| Cencora Inc COR | 46 | Elevated | Healthcare | United States | 5 / 6 | $61.8B |
| Takeda Pharmaceutical Company TAK | 50 | Elevated | Healthcare | Japan | 5 / 6 | $56.8B |
| Moderna Inc MRNA | 72 | Stretched | Healthcare | United States | 5 / 6 | $56.0B |
| Cardinal Health Inc CAH | 49 | Elevated | Healthcare | United States | 5 / 6 | $54.7B |
| Edwards Lifesciences Corp EW | 34 | Normal | Healthcare | United States | 5 / 6 | $52.3B |
| HOYA Corporation HYB | 25 | Normal | Healthcare | Japan | 5 / 6 | $51.3B |
| Becton Dickinson & Company BDX | 46 | Elevated | Healthcare | United States | 5 / 6 | $51.2B |
| Lonza Group AG LONN | 48 | Elevated | Healthcare | Switzerland | 5 / 6 | $51.2B |
| HOYA Corporation 7741 | 22 | Normal | Healthcare | Japan | 5 / 6 | $51.1B |
| Galderma Group N GALD | 38 | Normal | Healthcare | Switzerland | 5 / 6 | $49.5B |
| Galderma Group AG PY30 | 39 | Normal | Healthcare | Switzerland | 5 / 6 | $47.1B |
| Natera Inc NTRA | 38 | Normal | Healthcare | United States | 5 / 6 | $46.2B |
| Veeva Systems Inc - Class A VEEV | 24 | Normal | Healthcare | United States | 5 / 6 | $46.2B |
| Haleon plc HLN | 44 | Elevated | Healthcare | United Kingdom | 5 / 6 | $44.7B |
| Haleon PLC H6D0 | 45 | Elevated | Healthcare | United Kingdom | 4 / 6 | $44.2B |
| Idexx Laboratories Inc IDXX | 33 | Normal | Healthcare | United States | 5 / 6 | $43.9B |
| Agilent Technologies Inc A | 43 | Elevated | Healthcare | United States | 5 / 6 | $43.3B |
| IQVIA Holdings Inc IQV | 47 | Elevated | Healthcare | United States | 5 / 6 | $43.0B |
| Teva- Pharmaceutical Industries Ltd TEVA | 51 | Elevated | Healthcare | Israel | 4 / 6 | $42.0B |
| Waters Corp WAT | 42 | Elevated | Healthcare | United States | 5 / 6 | $40.7B |
| Otsuka Holdings Co. Ltd OS1 | 31 | Normal | Healthcare | Japan | 5 / 6 | $39.6B |
| BeiGene Ltd ONC | 17 | Contained | Healthcare | Switzerland | 5 / 6 | $37.5B |
| Sandoz Group AG D8Y0 | 43 | Elevated | Healthcare | Switzerland | 5 / 6 | $37.4B |
| Sandoz Group AG SDZ | 42 | Elevated | Healthcare | Switzerland | 5 / 6 | $36.9B |
| Alcon Inc ALC | 45 | Elevated | Healthcare | Switzerland | 4 / 6 | $34.8B |
| Resmed Inc RMD | 26 | Normal | Healthcare | United States | 5 / 6 | $34.6B |
| Dexcom Inc DXCM | 25 | Normal | Healthcare | United States | 5 / 6 | $34.4B |
| Illumina Inc ILMN | 40 | Elevated | Healthcare | United States | 4 / 6 | $32.3B |
| Alnylam Pharmaceuticals Inc ALNY | 22 | Normal | Healthcare | United States | 5 / 6 | $32.2B |
| GE HealthCare Technologies Inc GEHC | 49 | Elevated | Healthcare | United States | 5 / 6 | $32.2B |
| Biogen Inc BIIB | 36 | Normal | Healthcare | United States | 4 / 6 | $32.0B |
| Zoetis Inc - Class A ZTS | 37 | Normal | Healthcare | United States | 4 / 6 | $31.9B |
| Medline Inc - Class A MDLN | 56 | Elevated | Healthcare | United States | 5 / 6 | $30.7B |
| Mettler-Toledo International Inc MTD | 43 | Elevated | Healthcare | Switzerland | 5 / 6 | $28.2B |
| HANSOH PHARMAC. HD-00001 3KY | 19 | Contained | Healthcare | China | 5 / 6 | $27.6B |
| Royalty Pharma plc - Class A RPRX | 29 | Normal | Healthcare | United States | 4 / 6 | $27.4B |
| Laboratory Corp Of America Holdings LH | 44 | Elevated | Healthcare | United States | 5 / 6 | $26.9B |
| ROY.PHILIPS PHI1 | 53 | Elevated | Healthcare | Netherlands | 3 / 6 | $26.8B |
| Insmed Inc INSM | 63 | Stretched | Healthcare | United States | 4 / 6 | $26.6B |
| WuXi Biologics (Cayman) Inc. 2269.HK | 29 | Normal | Healthcare | Hong Kong | 5 / 6 | $26.5B |
| Quest Diagnostics Inc DGX | 44 | Elevated | Healthcare | United States | 5 / 6 | $26.4B |
| Koninklijke Philips N.V. PHG | 49 | Elevated | Healthcare | Netherlands | 5 / 6 | $26.0B |
| WUXI BIOLOGICS-00000083 1FW2 | 28 | Normal | Healthcare | China | 5 / 6 | $25.7B |
| BioNTech SE BNTX | 66 | Stretched | Healthcare | Germany | 5 / 6 | $25.5B |
| Roivant Sciences Ltd ROIV | 67 | Stretched | Healthcare | United Kingdom | 5 / 6 | $25.0B |
| Incyte Corp INCY | 13 | Contained | Healthcare | United States | 5 / 6 | $24.8B |
| West Pharmaceutical Services Inc WST | 43 | Elevated | Healthcare | United States | 5 / 6 | $24.0B |
| Innovent Biologics Inc 6IB | 15 | Contained | Healthcare | China | 5 / 6 | $23.4B |
| Sigma Healthcare Limited S5YA | 39 | Normal | Healthcare | Australia | 3 / 6 | $23.0B |
| Steris Plc STE | 36 | Normal | Healthcare | United States | 5 / 6 | $22.7B |
| Terumo Corporation TUO0 | 35 | Normal | Healthcare | Japan | 5 / 6 | $22.6B |
| United Therapeutics Corp UTHR | 28 | Normal | Healthcare | United States | 4 / 6 | $21.8B |
| Tenet Healthcare Corp THC | 38 | Normal | Healthcare | United States | 5 / 6 | $21.4B |
| Guardant Health Inc GH | 46 | Elevated | Healthcare | United States | 5 / 6 | $21.2B |
| GENMAB GE9 | 46 | Elevated | Healthcare | Denmark | 4 / 6 | $20.6B |
| Exact Sciences Corp EXAS | 46 | Elevated | Healthcare | United States | 5 / 6 | $20.0B |
| Genmab GMAB | 24 | Normal | Healthcare | Denmark | 5 / 6 | $19.8B |
| Viatris Inc VTRS | 74 | Stretched | Healthcare | United States | 4 / 6 | $19.1B |
| Zimmer Biomet Holdings Inc ZBH | 46 | Elevated | Healthcare | United States | 4 / 6 | $19.1B |
| Straumann Holding AG STMN | 40 | Elevated | Healthcare | Switzerland | 5 / 6 | $18.3B |
| Ascendis Pharma A/S ASND | 39 | Normal | Healthcare | Denmark | 5 / 6 | $17.3B |
| Sonova H Ag SOON | 43 | Elevated | Healthcare | Switzerland | 5 / 6 | $17.2B |
| Hologic Inc HOLX | 48 | Elevated | Healthcare | United States | 5 / 6 | $17.0B |
| Medpace Holdings Inc MEDP | 28 | Normal | Healthcare | United States | 5 / 6 | $16.5B |
| Swedish Orphan Biovitrum AB (publ) SOBI | 30 | Normal | Healthcare | Sweden | 4 / 6 | $16.4B |
| Jazz Pharmaceuticals plc JAZZ | 61 | Stretched | Healthcare | Ireland | 4 / 6 | $16.2B |
| Neurocrine Biosciences Inc NBIX | 17 | Contained | Healthcare | United States | 4 / 6 | $15.6B |
| Ipsen SA IPN | 29 | Normal | Healthcare | France | 5 / 6 | $15.5B |
By sector
Industrials 1,536Technology 1,292Healthcare 1,214Consumer Cyclical 1,116Basic Materials 577Communication Services 565Real Estate 552Consumer Defensive 536Energy 356Utilities 232
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.